ChromaDex Corporation (CDXC)
-OTC Markets 0.68 
0.03(3.95%) 2:58PM EDT
| Prev Close: | 0.71 |
|---|
| Open: | 0.72 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.68 - 0.72 |
|---|
| 52wk Range: | 0.50 - 1.25 |
|---|
| Volume: | 36,356 |
|---|
| Avg Vol (3m): | 123,011 |
|---|
| Market Cap: | 67.37M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SECFilings.com Insider Buy Breaking Alert: ChromaDex Director Buys 25,000 Shares in Open MarketMarketwired(Tue, May 21)
- ChromaDex To Present At The Second Annual Marcum LLP MicroCap ConferencePR Newswire(Mon, May 20)
- CHROMADEX CORP. FinancialsEDGAR Online Financials(Fri, May 17)
- ChromaDex® Reports Results for the First Quarter 2013PR Newswire(Fri, May 10)
- CHROMADEX CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- CHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- Spherix Announces New Agreements to Develop and Market D-tagatoseMarketwired(Thu, May 2)
- RedChip Announces Presentation Schedule for May 1 Emerging Growth ShowcaseGlobeNewswire(Tue, Apr 23)
- ChromaDex® Initiates First Human Clinical Study for Its New Caffeine Ingredient Technology, PURENERGY™PR Newswire(Thu, Apr 18)
- ChromaDex® Introduces New Caffeine Ingredient Technology, PURENERGY™PR Newswire(Mon, Apr 1)
- ChromaDex® Reports 2012 Full-Year Results and Closes Strategic Sale of Its BluScience™ Consumer Product LinePR Newswire(Fri, Mar 29)
- CHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Fri, Mar 29)
- Nuvilex: A Penny Stock That Could Be A Disease-Fighting Game Changerat Seeking Alpha(Fri, Mar 22)
- Dr. Nancy Booth of Spherix Consulting - a Division of ChromaDex® - Appointed to American Botanical Council Advisory BoardPR Newswire(Thu, Mar 21)
- ChromaDex® to Present at 25th Annual ROTH Conference on March 19, 2013PR Newswire(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.77 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ChromaDex Corporation, through its subsidiaries, provides research and quality-control products and services to the natural products industry. It offers bulk raw materials for inclusion in dietary supplements, food, beverage, and cosmetic products...
View More